Worldwide Clinical Trials, a Kohlberg‑backed contract research organization, agreed to acquire Catalyst Clinical Research, a private CRO with oncology expertise. The deal is another example of private equity–led consolidation among CROs aiming to build specialized capabilities and scale. Catalyst brings oncology trial experience that complements Worldwide’s global operations, creating a combined service set attractive to sponsors seeking end‑to‑end oncology trial execution. The transaction follows a string of M&A among clinical service providers as sponsors look to streamline vendor oversight and de‑risk complex oncology studies. Industry observers expect more roll‑ups as PE owners pursue platform plays and niche CROs seek distribution and capital to expand trial capacity.